SINOFUTURE PHARMA specialises in the production of steroidal, niche non-steroidal APIs. Our expertise extends to custom manufacturing solutions tailored to meet the specific needs of our clients. Presently, we operate 2 R&D centers and 2 manufacturing sites. Both sites have successfully passed inspections and audits for advanced intermediates and APIs by leading global pharmaceutical companies, including Novartis, as well as major European partners such as Sanofi, Roche.

As a professional GMP manufacturer of steroidal pharmaceuticals, we are dedicated to providing outstanding global distribution services for a comprehensive range of products, including Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and CDMO solutions.Our founding team possesses over a decade of industry experience, having successfully expanded into markets across Europe, the USA, and Australia, which has earned us a strong reputation and deep international expertise. We have established stable, long-term partnerships with many of the world's leading steroidal and peptide brands and remain committed to continuously strengthening these strategic relationships.

We operate a stable and compliant global supply chain, ensuring secure and reliable delivery for licensed pharmaceutical partners.With mature export experience and standardized logistics solutions, our materials are supplied with a high level of regulatory awareness and risk control.100% SAFE delivery coverage includes: USA (FDA-related markets), Canada (ANADA pathway), Australia (TGA), United Kingdom (MHRA), Paraguay, and major EU countries.All shipments are handled under strict compliance standards and are intended for B2B pharmaceutical, research, and manufacturing use only.

Working closely with partner manufacturers, providing professional consultation for DMF registration and EU-GMP compliance, including DMF compilation, submission, and deficiency response, gap analysis, pre-inspection, improvement strategies, during the whole drug lifecycle, including annual report and post-approval change, to ensure drug registration approval and GMP compliance in the international markets, e.g. US, Europe, Asia, Africa, etc.